{
  "docId": "019de070-6ba7-74d1-848b-b84c997820ae",
  "docSlug": "fd4b4c87c265fc439333e9f58c5ae8a7",
  "documentTitle": "Compass Therapeutics | IPO Presentation Deck | 40 slides",
  "authorId": "compass-therapeutics",
  "authorName": "Compass Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2020-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 40,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a before-after-bridge style framing to highlight the drug's superior efficacy compared to standard monotherapies.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de070-6ba7-74d1-848b-b84c997820ae/14",
  "deckHref": "/decks/019de070-6ba7-74d1-848b-b84c997820ae",
  "deckJsonHref": "/decks/019de070-6ba7-74d1-848b-b84c997820ae.json",
  "deckAnchorHref": "/decks/019de070-6ba7-74d1-848b-b84c997820ae#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.18,
        "y": 0.2
      },
      "kind": "image",
      "text": "Mouse with small tumor",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "16c2a15e-2974-40c1-862b-79351586ad2d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.57,
        "y": 0.2
      },
      "kind": "image",
      "text": "Mouse with large tumor",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0adab45-b89c-4102-81c8-847c7369c232",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.35,
        "x": 0.52,
        "y": 0.6
      },
      "kind": "list",
      "text": "Large CT26 tumor: ~500 mm3. Treating large tumors is generally considered futile. Highly resistant to monotherapy. Eradicated by CTX-471.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4c427acb-e952-4b02-ab89-84415e409a58",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.35,
        "x": 0.13,
        "y": 0.6
      },
      "kind": "list",
      "text": "Small CT26 tumor: ~75 mm3. Typical size at which treatment begins. Modestly sensitive to monotherapy. Eradicated by CTX-471.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a36bf068-0f79-4dc4-bc53-73ec511219a9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.85,
        "x": 0.02,
        "y": 0.03
      },
      "kind": "title",
      "text": "CTX-471 Demonstrated Promising Activity in Preclinical Models of High Tumor Burden",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ab22455-4ac9-4a95-878e-f64f46d53e3b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before/after framing",
      "slug": "before-after-framing",
      "agent": null,
      "layer": "slide",
      "matchId": "ae90bd2a-c45d-4ab1-9b29-4dcce51839ad",
      "evidence": "Comparison of small and large tumors",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "before-after-bridge",
      "slug": null,
      "matchId": "2e9a39f8-bcaa-4349-9c41-5e4cdb50e5b6",
      "evidence": "Contrasts standard treatment limitations with the success of the new drug.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 24,
      "from": 7,
      "beatId": "4189f97c-14ae-46e9-86c5-8cb495a87bea",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 7-24: Overview of Compass Proprietary Technologies, Pipeline, and clinical data",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    },
    {
      "to": 18,
      "from": 13,
      "beatId": "ec336838-4466-4bc9-8486-b974f1437248",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "Slides 13-18: CTX-471, a potential best-in-class CD137 agonist",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 40,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "8f23aa4f-73de-402c-b124-1353a7937adb",
      "evidence": "The deck presents a clear 'why' throughout, with a focus on the team's expertise and the pipeline's potential",
      "position": 1,
      "objective": "Why Compass Therapeutics, and why now?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}